In a study published in the New England Journal of Medicine, researchers conducted two parallel, 52-week, randomized double-blind trials with identical designs to investigate the efficacy of lebrikizumab in treating moderate-to-severe atopic dermatitis (AD). The trials followed a placebo-controlled, phase 3 approach, comprising a 16-week induction period and a 36-week maintenance period.
Is lebrikizumab a promising treatment option for patients with AD?